라이프
전체기사 보기-
Visa-Free Policies Fuel New Trend in Medical Tourism: International Patients Praise Parkway in Shanghai
SHANGHAI, Feb. 14, 2026 -- With the implementation of 144-hour visa-free transit across multiple cities in China, international visitors now enjoy significantly greater convenience. Recently, an intriguing trend has emerged: many foreign nationals arriving in Shanghai for business or tourism are now incorporating "health management" or "convenient medical access" into their packed itineraries, blurring the lines between "leisure travel to China" and "medical travel in China". Parkway MediCentre Xintiandi, located in the heart of downtown Shanghai, and P
- 김갑성 기자
- 2026-02-14 20:12
-
SingHealth Opens Community MRI Centre at Dunearn Village in Collaboration with United Imaging
SINGAPORE, Feb. 14, 2026 -- SingHealth, Singapore's largest public healthcare cluster, has opened a new MRI centre at Dunearn Village, marking its first MRI facility located outside a hospital campus and extending diagnostic imaging services into the community. Developed in collaboration with United Imaging Healthcare, a global provider of AI-powered medical imaging equipment and healthcare solutions, the centre introduces a new operational model designed to increase imaging capacity while improving patient experience and workflow efficiency. Fully licensed and operated by RADSC
- 김갑성 기자
- 2026-02-14 20:00
-
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
[ 메디채널 김갑성 기자 ] First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer. The designation covers gastric cancer broadly, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative subtypes.
- 김갑성 기자
- 2026-02-13 14:04
-
Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services
HONG KONG, Feb. 13, 2026 -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps preserve RNA integrity and cell viability, supporting high-quality single-cell data generation. Xenium™, develope
- 김갑성 기자
- 2026-02-13 14:00
-
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
[ 메디채널 김갑성 기자 ] - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulat
- 김갑성 기자
- 2026-02-13 08:00
-
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial is evaluating the company's developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line
- 김갑성 기자
- 2026-02-13 08:00
-
Waters, BD 생명과학 및 진단 솔루션 사업 부문과의 합병 성사
Claire M. Fraser 박사를 이사회 이사로 신규 선임 규제 환경에서의 고처리량 시험에 특화된 글로벌 생명과학 및 진단 분야 선도 기업으로 도약 4개 사업부 신설 발표: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, Waters Materials Sciences 매사추세츠주 밀퍼드, 2026년 2월 13일 -- Waters Corporation(NYSE: WAT)(이하 "Waters")은 오늘 Becton, Dickinson and Company(NYSE: BDX)(이하 "BD")의 생명과학 및 진단 솔루션 사업 부문과의 합병 절차를 완료했다고 밝혔다. 이번 합병으로 최고 수준의 기술력과 업계를 선도하는 재무 전망을 갖춘 글로벌 생명과학 및 진단 분야의 선도 기업이 출범하게 되었다. 또한 회사는 Claire M. Fraser 박사의 이사회(이하 "Waters 이사회") 이사 선임을 발표했으며, 이에 따라 Waters 이사회의 구성 인원은 총 11명으로 확대되었다.&
- 김갑성 기자
- 2026-02-13 07:00
-
SleepAI.com Introduces an AI-Powered Sleep and Emotional Wellness Platform for Modern Life
LOS ANGELES, Feb. 13, 2026 -- SleepAI.com, a personalized AI sleep companion, today announced the launch of an AI-powered sleep and emotional wellness platform, now available on both the iOS and Google Play app stores. The platform is designed to address one of modern life's most persistent challenges: the growing disconnect between how people live and how they sleep. Redefining Sleep Tech: A Custom-Built, End-to-End Intelligent Management Ecosystem SleepAI.com moves beyond traditional sleep apps that rely primarily on static audio content. Instead, the platform delivers
- 김갑성 기자
- 2026-02-13 02:00
-
Datasea Reports Second Fiscal Quarter 2026 Results
Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalization, today announced its unaudited financial results for the second fiscal quarter and the six months ended December 31, 2025. Additional details will be available in the Company's Quarterly Report on Form 10-Q as filed with the SEC. Six Month Fiscal 2026 High
- 김갑성 기자
- 2026-02-12 22:20
-
Ubie Announces Collaboration to Reinvent the Healthcare Digital Front Door
Ubie and Mayo Clinic collaborate with the goal of delivering a unified, AI-powered chat and voice platform to streamline healthcare access, reduce complexity and offer a best-in-class patient experience Natural conversations, instant answers, and a seamless triage-to-booking flow will drive first-contact resolution, self-scheduling and patient satisfaction scores NEW YORK, Feb. 12, 2026 -- Ubie, an AI-driven and clinically vetted healthcare prediction platform designed to guide patients to the care they need, today announced a collaboration with Mayo Clinic to co-develo
- 김갑성 기자
- 2026-02-12 22:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-02-14_SAT
- Milano Cortina 2026 Licensed Candies Released Globally 22:40
- Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 20:58
- Visa-Free Policies Fuel New Trend in Medical Tourism: International Patients Praise Parkway in Shanghai 20:12
- SingHealth Opens Community MRI Centre at Dunearn Village in Collaboration with United Imaging 20:00
- Tower Capital Asia社、デジタルIDおよびモバイルアプリケーションセキュリティのリーダー企業であるV-Key社への過半数出資を発表 17:15
- 타워 캐피털 아시아, 디지털 신원 및 모바일 애플리케이션 보안 선도 기업 브이키에 다수 지분 투자 발표 12:37
- Cboe、Russell 2000指数オプションのほぼ24時間取引を開始 00:23
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 02월 15일 00시 20분